Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff

X
Trial Profile

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spartalizumab (Primary) ; Tislelizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms ACROPOLI
  • Most Recent Events

    • 24 Oct 2023 Results assessing genes or gene expression signatures that can effectively indicate TLS abundance in the TME, irrespective of the cancer type in patients with advanced solid cancer participating in the molecular prescreening of this trial presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results of exploratory analysis (n=1003) assessing the correlation between the presence of TILs and gene expression across multiple cancer types presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results (n=58) assessing Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top